Many of the patients we'd expect to have elevated hs-CRP were exluded from the CANTOS trial. The exclusion of patients on other anti-inflammatory drugs likely excluded most patients with active rheumatologic disease. Further, patients with infections (chronic and acute) and with history of malignancy were excluded. Of the patients who were not excluded, why do they have elevated hs-CRP? In terms of CVD risk and impact of canakinumab, do you think the underlying cause matters?
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.